ARAY (Accuray) Other Current Receivables: $0.0 Mil (As of Mar. 2026)


ARAY Accuray Inc ARAY
44 GF Score
Price $0.25
GF Value $1.34
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Accuray Other Current Receivables?

Accuray ARAY -9.32% 44 Other Current Receivables is $0.0 Mil as of Mar. 2026. GuruFocus rates ARAY with a GF Score™ of 44/100 and a GF Value™ of $1.34 (Possible Value Trap). The stock has 6 warning signs investors should review.

Accuray's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.0 Mil.

Accuray's quarterly Other Current Receivables increased from Sep. 2025 ($6.78 Mil) to Dec. 2025 ($17.88 Mil) but then stayed the same from Dec. 2025 ($17.88 Mil) to Mar. 2026 ($0.00 Mil).

Accuray's annual Other Current Receivables declined from Jun. 2023 ($12.52 Mil) to Jun. 2024 ($6.85 Mil) but then increased from Jun. 2024 ($6.85 Mil) to Jun. 2025 ($14.68 Mil).

Accuray Other Current Receivables Related Terms

Accuray Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Accuray's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accuray Other Current Receivables Chart

Accuray Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.35 7.06 12.52 6.85 14.68

Accuray Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.79 14.68 6.78 17.88 0.00
ARAY
44GF Score
Accuray Inc ARAY
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accuray Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.0 Mil mean?
Accuray (ARAY) has a Other Current Receivables of $0.0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Accuray and its competitors.
Is Accuray's Other Current Receivables too high?
Accuray's current Other Current Receivables is $0.0 Mil. Overall, Accuray has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accuray's Other Current Receivables compare to PETV and NSPR?
Accuray's Other Current Receivables of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Accuray and its competitors. Accuray's current Other Current Receivables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accuray stock overvalued right now?
Based on GuruFocus' analysis, Accuray (ARAY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.34, compared to a current price of $0.25 — trading 81.3% below its estimated fair value. The current Other Current Receivables is $0.0 Mil. Accuray's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Accuray (ARAY), the current Other Current Receivables is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Accuray (ARAY) Overvalued in 2026?

Based on GuruFocus' analysis, Accuray stock appears to be undervalued. The current stock price of $0.25 is trading 81.3% below its estimated GF Value™ of $1.34. GuruFocus considers Accuray to be Possible Value Trap.

Key valuation signals for ARAY:

  • Other Current Receivables: $0.0 Mil
  • GF Value™: $1.34 vs. price of $0.25 (81.3% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the ARAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Accuray Business Description

Other Exchanges 0H8I:UKXEJ:Germany
Address 1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
44GF Score

Get the complete analysis for ARAY

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$1.34
GF Value